Supplementary Material
toxicity
Study design, dose escalation, and confirmatory dosing cohorts (Part A) for CB-103Click here for additional data file.Pharmacokinetic parametersClick here for additional data file.Biomarkers of Clinical Benefit for ACC patientsClick here for additional data file.Safety and toxicity monitoring throughout the CB-103 clinical tria1Click here for additional data file.Pharmacokinetic parameters for CB-103Click here for additional data file.Pharmacodynamic and biomarker assessments: percent change in peripheral Notch target gene expression in circulation across individual patients (each row) on twice daily dosing of CB-103Click here for additional data file.Representativeness of Study ParticipantsClick here for additional data file.